Anti-inflammatory, but not lipid-lowering, activity of hepatocyte PPARα improves atherosclerosis in Ldlr-deficient mice
Hepatic inflammation-targeting pemafibrate reduces atherosclerosis in Ldlr−/− mice, supporting a role for inflammation in cardiovascular risk.